BLUE – bluebird bio, inc. (US:NASDAQ)
Stock Stats
News
4/16
08:00 am
blue
Medium
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
4/14
08:32 am
blue
Medium
Beyond Science: Making Cell And Gene Therapy Economically Viable [Forbes]
4/13
01:15 am
blue
Medium
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/5
02:05 am
blue
Low
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/31
10:45 am
blue
Medium
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $40.00 to $8.00. They now have an "overweight" rating on the stock.
11/14/2024
07:00 am
blue
-7.7%
BEAT
3/31
10:42 am
Maintains
Overweight
Overweight
Barclays
Medium
-4.8%
3/31
10:42 am
Maintains
Overweight
Overweight
Barclays
Medium
-4.8%
2/24
01:10 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Medium
8.9%
2/24
01:10 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Medium
8.9%
2/24
07:07 am
Upgrades
Underweight
Neutral
JPMorgan Chase & Co.
Low
1.0%
4/16
08:13 am
blue
Low
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
4/16
07:41 am
blue
Medium
Form SC TO-T/A bluebird bio, Inc. Filed by: Carlyle Partners Growth, L.P.
4/10
04:59 pm
blue
High
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
4/3
07:50 am
blue
Low
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
4/3
07:38 am
blue
Low
Form SC TO-T/A bluebird bio, Inc. Filed by: Carlyle Partners Growth, L.P.
Show more
Top News Gainers
12/10 bluebird bio Inc (NASDAQ: BLUE) had its "hold" rating re-affirmed by analysts at William Blair. 13.2%
4/8 Form 4 bluebird bio, Inc. For: Apr 06 Filed by: Smith-Farrell Joanne 9.3%
2/1 bluebird bio Inc (NASDAQ: BLUE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.1%
6/6 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ßA-T87Q-globin gene) Approval 8.1%
12/13 bluebird bio Inc (NASDAQ: BLUE) was upgraded by analysts at Oppenheimer Holdings Inc. to a "buy" rating. They now have a $135.00 price target on the stock. 7.0%
12/23 Form 4 bluebird bio, Inc. For: Dec 19 Filed by: WENTWORTH KORY JAMES 6.1%
6/13 bluebird bio Inc (NASDAQ: BLUE) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $195.00 price target on the stock. 5.5%
5/16 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress 4.8%
10/31 Form 8-K bluebird bio, Inc. For: Oct 31 4.6%
6/14 Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC] 4.3%
Top News Decliners
12/7 bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition -12.0%
2/18 Form 8-K bluebird bio, Inc. For: Feb 18 -9.7%
10/23 bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh -8.7%
8/21 Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. -7.3%
6/18 Maxim turns bullish on Bluebird [Seeking Alpha] -6.8%
4/27 Form DEF 14A bluebird bio, Inc. For: Jun 18 -6.8%
6/7 Form 4 bluebird bio, Inc. For: Jun 05 Filed by: Gregory Philip D -6.4%
8/1 Q2/2019 6/30/2019 EPS -3.550 ZacksConsensus -3.030 ActVsEst (0.520) - Miss -6.1%
6/14 Form 8-K bluebird bio, Inc. For: Jun 14 -5.8%
1/13 Form 8-K bluebird bio, Inc. For: Jan 13 -5.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3